RALES Score (Spironolactone Benefit Predictor)

RALES Score (Spironolactone Benefit Predictor): Explanation and Clinical Context The RALES Score is a clinical tool designed to estimate the survival benefit and safety of spironolactone therapy in patients with advanced heart failure (NYHA class III–IV) and reduced ejection fraction. It is conceptually derived from the Randomized Aldactone Evaluation Study (RALES), published in the New England Journal of Medicine in 1999. The RALES trial demonstrated that adding spironolactone (25 mg/day) to standard heart failure therapy (ACE inhibitors, loop diuretics, digoxin) reduced all-cause mortality by 30% and hospitalizations for heart failure by 35%.

This benefit was most pronounced in patients with higher baseline neurohormonal activation (hyponatremia, low LVEF) and without severe renal dysfunction or hyperkalemia. Contraindications include serum creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women) and serum potassium ≥5.0 mmol/L. In these patients, spironolactone increases the risk of life-threatening hyperkalemia and should be avoided.

The calculator provides an approximate clinical prediction of spironolactone benefit by integrating renal function, electrolyte status, NYHA class, and age. The estimated relative risk reduction and number needed to treat (NNT) are adapted from subgroup analyses and regression modeling from the RALES dataset, offering an individualized yet pragmatic estimation for bedside decision-making.